---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-24-000164"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:38:33.618252+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PacBio Q2 revenue down 24% to $36M; GAAP net loss $173M includes $93M goodwill impairment

## Summary
- Revenue of $36.0M vs $47.6M YoY; instrument revenue fell to $14.7M from $29.9M.
- GAAP net loss $173.3M (-$0.64/sh); non-GAAP net loss $55.2M (-$0.20/sh).
- Goodwill impairment charge of $93.2M; restructuring expenses of $18.0M included.
- Cash $509.8M, down from $631.4M at Dec 31, 2023.
- CEO expects revenue acceleration in H2; targeting >$75M annual expense reduction.

## SEC filing metadata
- accession: 0001299130-24-000164
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913024000164/0001299130-24-000164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913024000164/pacb-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-24-000164
- JSON: https://secwatch.observer/filing/0001299130-24-000164.json
- Plain text: https://secwatch.observer/filing/0001299130-24-000164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.